LONDON, Nov 20 (Reuters) - Approval for Johnson & Johnson to sell its pain medicine Ionsys in Europe should be suspended because of a defect with the drug's delivery system that could lead to overdose, the European Medicines Agency (EMEA) said on Thursday.